These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 28002131)

  • 21. Prevention of acute adverse events related to infliximab infusions in pediatric patients.
    Lahdenne P; Wikström AM; Aalto K; Kolho KL
    Arthritis Care Res (Hoboken); 2010 Jun; 62(6):785-90. PubMed ID: 20535789
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The association of infliximab trough levels with disease activity in pediatric inflammatory bowel disease.
    Hoekman DR; Brandse JF; de Meij TG; Hummel TZ; Löwenberg M; Benninga MA; D'Haens GR; Kindermann A
    Scand J Gastroenterol; 2015; 50(9):1110-7. PubMed ID: 25865965
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Safety and Tolerability of Accelerated Infliximab Infusions in Patients With Inflammatory Bowel Disease.
    Ma D; Wong W; Aviado J; Rodriguez C; Wu H
    Am J Gastroenterol; 2019 Feb; 114(2):352-354. PubMed ID: 30333541
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Current practice and perception of screening for medication adherence in inflammatory bowel disease.
    Trindade AJ; Morisky DE; Ehrlich AC; Tinsley A; Ullman TA
    J Clin Gastroenterol; 2011; 45(10):878-82. PubMed ID: 21555953
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Outcomes From Pediatric Gastroenterology Maintenance of Certification Using Web-based Modules.
    Sheu J; Chun S; O'Day E; Cheung S; Cruz R; Lightdale JR; Fishman DS; Bousvaros A; Huang JS
    J Pediatr Gastroenterol Nutr; 2017 May; 64(5):671-678. PubMed ID: 27977544
    [TBL] [Abstract][Full Text] [Related]  

  • 26. 5-Aminosalicylates and renal function monitoring in inflammatory bowel disease: a nationwide survey.
    Zallot C; Billioud V; Frimat L; Faure P; Peyrin-Biroulet L;
    J Crohns Colitis; 2013 Aug; 7(7):551-5. PubMed ID: 22999780
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Distinct Thresholds of Infliximab Trough Level Are Associated with Different Therapeutic Outcomes in Patients with Inflammatory Bowel Disease: A Prospective Observational Study.
    Roblin X; Boschetti G; Duru G; Williet N; Deltedesco E; Phelip JM; Peyrin-Biroulet L; Nancey S; Flourié B; Paul S
    Inflamm Bowel Dis; 2017 Nov; 23(11):2048-2053. PubMed ID: 28945636
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pneumocystis jiroveci pneumonia in patients with inflammatory bowel disease: a survey of prophylaxis patterns among gastroenterology providers.
    Okafor PN; Wasan SK; Farraye FA
    Inflamm Bowel Dis; 2013; 19(4):812-7. PubMed ID: 23435401
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prescribing patterns and awareness of adverse effects of infliximab: a health survey of gastroenterologists.
    Donovan M; Lunney K; Carter-Pokras O; Cross RK
    Dig Dis Sci; 2007 Aug; 52(8):1798-805. PubMed ID: 17417731
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Infliximab safety profile and long-term applicability in inflammatory bowel disease: 9-year experience in clinical practice.
    Zabana Y; Domènech E; Mañosa M; Garcia-Planella E; Bernal I; Cabré E; Gassull MA
    Aliment Pharmacol Ther; 2010 Mar; 31(5):553-60. PubMed ID: 20002026
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Premedication with intravenous steroids does not influence the incidence of infusion reactions following infliximab infusions in pediatric inflammatory bowel disease patients-a case-control study.
    van Wassenaer EA; Meester VL; Kindermann A; Koot BGP; Benninga MA; de Meij TGJ
    Eur J Clin Pharmacol; 2019 Oct; 75(10):1445-1450. PubMed ID: 31332475
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A national survey of practice patterns of gastroenterologists with comparison to the past two decades.
    Russo MW; Gaynes BN; Drossman DA
    J Clin Gastroenterol; 1999 Dec; 29(4):339-43. PubMed ID: 10599638
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [PREMEDICATION WITH CORTICOSTEROIDS PRIOR TO IV INFLIXIMAB - A COMPARISON BETWEEN INFLAMMATORY BOWEL DISEASE (IBD) AND RHEUMATIC PATIENTS].
    Oshri D; Schwarz D; Vodonos A; Zimhony N; Abu-Shakra M; Zeller L
    Harefuah; 2019 Sep; 158(9):571-575. PubMed ID: 31507106
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Safety of ferric carboxymaltose immediately after infliximab administration, in a single session, in inflammatory bowel disease patients with iron deficiency: a pilot study.
    Cortes X; Borrás-Blasco J; Molés JR; Boscá M; Cortés E
    PLoS One; 2015; 10(5):e0128156. PubMed ID: 26011514
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The Effectiveness of Methylprednisolone as a Premedication Among the Pediatric Population for Preventing Infusion-Related Reactions to Infliximab.
    Zeng-Wang YM; Cares K; Thomas R; El-Baba M
    Gastroenterol Nurs; 2021 Nov-Dec 01; 44(6):449-454. PubMed ID: 34690297
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Switching Between Infliximab Originator and Biosimilar in Paediatric Patients with Inflammatory Bowel Disease. Preliminary Observations.
    Sieczkowska J; Jarzębicka D; Banaszkiewicz A; Plocek A; Gawronska A; Toporowska-Kowalska E; Oracz G; Meglicka M; Kierkus J
    J Crohns Colitis; 2016 Feb; 10(2):127-32. PubMed ID: 26721942
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Physicians' Knowledge and Application of Immunization Strategies in Patients with Inflammatory Bowel Disease: A Survey of the Italian Group for the Study of Inflammatory Bowel Disease.
    Macaluso FS; Mazzola G; Ventimiglia M; Alvisi P; Renna S; Adamoli L; Galli M; Armuzzi A; Ardizzone S; Cascio A; Cottone M; Orlando A;
    Digestion; 2020; 101(4):433-440. PubMed ID: 31167191
    [TBL] [Abstract][Full Text] [Related]  

  • 38. IgE antibodies and skin tests in immediate hypersensitivity reactions to infliximab in inflammatory bowel disease: impact on infliximab retreatment.
    Fréling E; Peyrin-Biroulet L; Poreaux C; Morali A; Waton J; Schmutz JL; Guéant JL; Barbaud A
    Eur J Gastroenterol Hepatol; 2015 Oct; 27(10):1200-8. PubMed ID: 26181108
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy and Safety of the Biosimilar Infliximab CT-P13 Treatment in Inflammatory Bowel Diseases: A Prospective, Multicentre, Nationwide Cohort.
    Gecse KB; Lovász BD; Farkas K; Banai J; Bene L; Gasztonyi B; Golovics PA; Kristóf T; Lakatos L; Csontos ÁA; Juhász M; Nagy F; Palatka K; Papp M; Patai Á; Lakner L; Salamon Á; Szamosi T; Szepes Z; Tóth GT; Vincze Á; Szalay B; Molnár T; Lakatos PL
    J Crohns Colitis; 2016 Feb; 10(2):133-40. PubMed ID: 26661272
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Frequency and characteristics of infusion reactions during biosimilar infliximab treatment in inflammatory bowel diseases: results from Central European nationwide cohort.
    Bálint A; Rutka M; Végh Z; Kürti Z; Gecse KB; Banai J; Bene L; Gasztonyi B; Kristóf T; Lakatos L; Miheller P; Palatka K; Patai Á; Salamon Á; Szamosi T; Szepes Z; Tóth GT; Vincze Á; Bor R; Milassin Á; Fábián A; Nagy F; Kolar M; Bortlik M; Duricova D; Hruba V; Lukas M; Mitrova K; Malickova K; Lukas M; Lakatos PL; Molnár T; Farkas K
    Expert Opin Drug Saf; 2017 Aug; 16(8):885-890. PubMed ID: 28504555
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.